Article content

VERU stock chart

Biotech Stocks To Watch Week of February 11 2019: $MTFB $VERU $PFE $BHC $MRK $CALA $GMDA $BCRX $AIMT

Next week we have the Genitourinary (GU) Cancers Symposium, a three-day meeting for GU malignancies, from February 14 – 16, 2019. Lots of traders will be watching the data released from Merck and its Phase 3 KEYNOTE-426 trial of Keytruda in combination with axitinib in patients with advanced or metastatic renal cell carcinoma. Sympathy plays may be Exelixis (EXEL) and Bristol-Myers Squibb Company (BMY).

The biotech ETF IBB has formed a Double Top off its 200 day moving average line.

IBB stock chart

200 day moving average resistance has held since early November 2018. Keep your eyes on 106 area support as a break below this level could signal a risk-off market and big pullback in biotech stocks.

9 Biotech Stocks To Watch

Below is a list of nine biotechnology stocks to watch the week of February 11, 2019. These stocks could have either explosive moves up or down depending on the results of the data release.

MTFB Stock

Iclaprim – REVIVE-2 for acute bacterial skin and skin structure infections (ABSSSI). PDUFA date February 13, 2019.

The FDA has accepted for filing the New Drug Application (NDA) for iclaprim, a targeted, Gram-positive investigational antibiotic, for the treatment of acute bacterial skin and skin structure infections (ABSSSI). This means that the FDA has determined that the application is sufficiently complete to perform a substantive review. The NDA has been granted Priority Review, and the FDA has set a target decision date under the Prescription Drug User Fee Act (PDUFA) of February 13, 2019.

“The NDA acceptance by the FDA is an important milestone for Motif Bio and reflects the dedication and commitment of our team who have worked tirelessly to accomplish this,” said Graham Lumsden, Chief Executive Officer of Motif Bio. “We believe that, if approved, iclaprim could be an important new treatment option for patients with serious skin infections. We look forward to working closely with the FDA as we move through the review process with the goal of bringing iclaprim to patients as quickly as possible.”

More than 3.6 million patients with ABSSSI are hospitalised annually in the U.S. It is estimated that up to 26% of hospitalised ABSSSI patients have renal impairment. Hospitalised patients with obesity, diabetes and/or poor kidney function are particularly vulnerable to vancomycin-associated kidney injury. Many standard of care Gram-positive antibiotics are not suitable for treatment of hospitalised ABSSSI patients with these conditions due to efficacy and/or safety issues.

The NDA includes data from two Phase 3 trials (REVIVE-1 and REVIVE-2) evaluating iclaprim for the treatment of patients with ABSSSI. In both trials, iclaprim achieved the primary endpoint of non-inferiority (NI) (10% margin) compared to vancomycin, the current standard of care, at the early time point (ETP), 48 to 72 hours after the start of administration of the study drug, in the intent-to-treat (ITT) patient population. Iclaprim also achieved NI (10% margin) at the test of cure endpoint, 7 to 14 days after study drug discontinuation, in the ITT patient population.

Iclaprim has received Qualified Infectious Disease Product (QIDP) designation from the FDA. If iclaprim is approved as a new chemical entity with QIDP designation, it will be eligible for 10 years of market exclusivity in the U.S. starting from the date of approval, under the Generating Antibiotic Incentives Now Act (the GAIN Act).

MTFB stock chart

MTFB stock has already started its upward move from when I first wrote about it on January 27, 2019 here. MTFB was at $9.86, today it’s at $10.90 which is a +10% upward move. Price movement has been a little bit too volatile to find a nice entry and exit point as it’s already moving higher. It is probably a good idea to wait for a consolidation first.

VERU Stock

Zuclomiphene citrate for hot flashes. Phase 2 poster will be at ASCO Genitourinary, February 14, 2019.

Four abstracts have been accepted for poster presentation at the upcoming 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium to be held February 14-16, 2019, at the Moscone West Building in San Francisco, California.

Three of the presentations will be for VERU-111, the Company’s proprietary, next generation, first-in-class selective oral tubulin inhibitor for the treatment of advanced prostate cancer which is enrolling in a Phase1b/2 clinical study, and the fourth presentation will be for zuclomiphene citrate (VERU-944), a proprietary oral estrogen receptor agonist drug for the treatment of hot flashes caused by androgen deprivation therapy (ADT) for men with advanced prostate cancer which is currently enrolling in a Phase 2 clinical trial.

Additional information on the meeting can be found on the ASCO Genitourinary Cancers Symposium website: https://gucasym.org/. The full abstracts will be made available online via https://meetinglibrary.asco.org at 5:00 PM (EST) on February 11, 2019.

Presentation details:

  1. Abstract Title: Design of Phase 1b/2 study of oral VERU-111, an α and β-tubulin inhibitor, for the treatment of metastatic castration and androgen blocking agent resistant prostate cancer.
    Presenter: Mark Markowski, MD, PhD, Assistant Professor of Oncology, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Abstract Number: TPS330
    Board Number: N6
    Session Information: Poster Session A: Prostate Cancer
    Date/Time: February 14, 2019 – 11:30 AM – 1:00 PM and 5:30 PM – 6:30 PM
  2. Abstract Title: VERU-111, a novel oral inhibitor of α and β tubulin, inhibits tumor growth in the human castration-resistant AR variant prostate cancer (PCa) model 22Rv1
    Presenter: Mark Markowski, MD, PhD, Assistant Professor of Oncology, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Abstract Number: 167
    Board Number: G10
    Session Information: Poster Session A: Prostate Cancer
    Date/Time: February 14, 2019 – 11:30 AM – 1:00 PM and 5:30 PM – 6:30 PM

  3. Abstract Title: The oral α and β tubulin inhibitor, VERU-111, demonstrates no neutropenia, myelosuppression or abnormal liver function in doses being evaluated for the treatment of metastatic castration resistant prostate cancer in nonclinical toxicity studies.
    Presenter: Robert H. Getzenberg, PhD, Executive Associate Dean for Research and Professor of Medicine, Patel College of Medicine, Nova Southeastern University
    Abstract Number: 299
    Board Number: D7
    Session Information: Poster Session B: Prostate Cancer; Urothelial Carcinoma, Penile, Urethral, Testicular and Adrenal Cancers
    Date/Time: February 15, 2019 – 12:15 PM – 1:45 PM and 5:15 PM – 6:15 PM
  4. Abstract Title: A Phase 2, dose finding, placebo-controlled, study of Zuclomiphene citrate to ameliorate the frequency and severity of hot flashes caused by androgen deprivation in men with advanced prostate cancer.
    Presenter: Robert H. Getzenberg, PhD, Executive Associate Dean for Research and Professor of Medicine, Patel College of Medicine, Nova Southeastern University
    Abstract Number: TPS338
    Board Number: N14
    Session Information: Poster Session A: Prostate Cancer
    Date/Time: February 14, 2019 – 11:30 AM – 1:00 PM and 5:30 PM – 6:30 PM

VERU-111 is a novel, proprietary, next generation, first-in-class oral selective antitubulin agent that targets and disrupts alpha and beta tubulin subunits of microtubules. In cancer cells, microtubules are critical for transport of growth factor receptors, cellular proliferation, and metastases. In preclinical effectiveness and toxicity studies, orally administered VERU-111 demonstrated significant antitumor activity against castration and novel androgen blocking agent (abiraterone or enzalutamide) resistant human prostate cancers. Furthermore, VERU-111 had significant antitumor effects against cancers that overexpress multidrug resistant proteins, like P-glycoprotein, a common mechanism by which cancer cells become resistant to cancer drugs. At oral doses that had significant antitumor effects, VERU-111 had a favorable safety profile as it did not cause neutropenia or myelosuppression, common dose limiting side effects of other classes of commercially available antitubulins such as intravenous taxanes or intravenous vinca alkaloids.

Veru is conducting an open label Phase1b/2 clinical trial evaluating the safety and effectiveness of VERU-111 in men who have metastatic castration resistant prostate cancer who have also become resistant to novel androgen blocking agents like abiraterone or enzalutamide. In addition to prostate cancer, VERU-111 had antitumor effects in other cancer types including preclinical human models for triple negative breast cancer, ovarian cancer and pancreatic cancer. VERU-111 has the potential to be the first FDA approved selective antitubulin agent that targets and disrupts alpha and beta tubulin subunits of microtubules to treat cancer.

Zuclomiphene citrate (VERU-944) is a novel, proprietary, oral, nonsteroidal, estrogen receptor agonist being evaluated in a Phase 2 clinical study to treat hot flashes, one of the most common side effects caused by androgen deprivation therapy (ADT), or hormone treatment for men with advanced prostate cancer. The Phase 2 clinical trial will enroll approximately 120 men in over 15 clinical sites in the United States. Zuclomiphene citrate has the potential to be the first FDA approved drug for hot flashes caused by prostate cancer hormone therapy. It is estimated that there are over 600,000 men in the US on ADT and about 30% of them suffer from moderate to severe hot flashes. Concern over hot flashes make men less likely to begin ADT and can lead to early discontinuation of this effective prostate cancer therapy. Based on an independent market analysis sponsored by the Company, the Company estimates the US market potential for zuclomiphene citrate is over $600 million annually.

VERU stock chart

VERU stock shows an ok setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. A pullback is taking place, which may present a nice opportunity for an entry. There is a resistance zone just above the current price starting at $1.54. Right above this resistance zone may be a good entry point.

PFE Stock

XTANDI (ARCHES) for metastatic hormone sensitive prostate cancer. Phase 3 trial met primary endpoint on December 20, 2018. Poster at ASCO GU February 14, 2019.

KEYTRUDA and Inlyta – KEYNOTE-426 for renal cell carcinoma. Phase 3 trial met primary endpoints of PFS and OS. Data to be presented February 16, 2019 at ASCO Genitourinary Cancers Symposium.

PFE stock

PFE stock has an ok setup on the chart. Prices have been consolidating lately. There is a resistance zone just above the current price starting at $42.47. Right above this resistance zone may be a good entry point.

BHC Stock

DUOBRII (halobetasol propionate and tazarotene) for psoriasis. CRL issued on June 18, 2018. PDUFA date is set for February 15, 2019.

Back on August 29, 2018, Bausch Health Companies announced that the FDA has accepted the resubmitted New Drug Application (NDA) for DUOBRIITM1 (halobetasol propionate and tazarotene) (IDP-118) Lotion for the topical treatment of plaque psoriasis. The FDA accepted the application as a Class 2 resubmission, with a PDUFA action date of February 15, 2019.

“We are confident in our NDA resubmission for DUOBRII and unwavering in our commitment to bring this new treatment option to patients,” said Bill Humphries, president, Ortho Dermatologics. “We have worked closely with the FDA to answer their questions regarding pharmacokinetic data, and we look forward to continued collaboration with the Agency through the remainder of the review process.”

If approved, DUOBRII will be the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation for the treatment of plaque psoriasis in adult patients, allowing for a potentially expanded duration of use.

Ortho Dermatologics, a Bausch Health company, is one of the largest prescription dermatology businesses in the world dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Ortho Dermatologics portfolio includes several leading acne, anti-fungal and anti-infective products.

BHC stock

BHC stock is not a setup right now. Price movement has been a little bit too volatile to find a nice entry and exit point. It is probably a good idea to wait for a consolidation first.

MRK Stock

KEYTRUDA and Inlyta – KEYNOTE-426 for renal cell carcinoma. Phase 3 trial met primary endpoints of PFS and OS. Data to be presented February 16, 2019 at ASCO Genitourinary Cancers Symposium.

KEYTRUDA – EORTC1325/KEYNOTE-054 for melanoma. PDUFA date February 16, 2019.

Merck will present data from the pivotal Phase 3 KEYNOTE-426 trial, studying KEYTRUDA in combination with axitinib in patients with advanced or metastatic renal cell carcinoma at the annual American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco in an oral session on February 16, 2019.

The FDA accepted for standard review a new sBLA for KEYTRUDA as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a PDUFA date of February 16, 2019. This sBLA is based on a significant benefit in recurrence-free survival demonstrated by KEYTRUDA in the pivotal Phase 3 EORTC1325/ KEYNOTE-054 trial, which was conducted in collaboration with the European Organisation for Research and Treatment of Cancer.

MRK stock

MRK stock is not a good setup right now. Price movement has been a little bit too volatile to find a nice entry and exit point. It is better to wait for a consolidation first.

CALA Stock

CB-839 + Cabozantinib (CANTATA) for renal cell carcinoma. Phase 2 poster at ASCO GU on February 16, 2019.

CALA stock

CALA stock is not a good setup. Price movement has been a little bit too volatile to find a nice entry and exit point. It is probably a good idea to wait for a consolidation first.

GMDA Stock

NAM-NK Non-Hodgkin lymphoma; Multiple myeloma. Phase 1 updated data due at TCT meeting February 20, 2019.

Gamida Cell announced that new data from its clinical programs will be presented at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR) taking place in Houston, Texas, February 20 – 24, 2019.

During the meeting, new data will be presented from the ongoing Phase 1 study of NAM-NK, an investigational, cell-based cancer immunotherapy, in patients with non-Hodgkin lymphoma and multiple myeloma. Additionally, there will be two presentations on NiCord®, an investigational universal bone marrow donor source, including an oral presentation describing translational data from the completed Phase 1/2 study of NiCord in patients with high-risk hematologic malignancies, or blood cancers. Initial data from a Phase 1/2 study of NiCord in patients with severe aplastic anemia will also be presented.

“We are pleased with our continued progress with NiCord, our late-stage development program in bone marrow transplantation, and we are encouraged by the clinical profile of NAM-NK that is emerging from this first Phase 1 clinical study,” stated Ronit Simantov, M.D., chief medical officer at Gamida Cell. “Collectively, the data that will be presented next month reinforce our belief that our proprietary nicotinamide, or NAM, cell expansion technology has the potential to deliver transformative treatments to patients.”

Details about the presentations are as follows:

Time: Wednesday, February 20, 2019, 9:00 a.m. – 5:00 p.m. CT (poster displayed) and 6:45 p.m. – 7:45 p.m. CT (presentation)
Title: First-in-Human Phase I Study of Nicotinamide-Expanded Related Donor Natural Killer Cells for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma
Poster Number: 242
Lead Author: Veronika Bachanova, M.D., Ph.D., associate professor of medicine, division of hematology, oncology and transplantation, University of Minnesota
Location: George R. Brown Convention Center, Level 3, Hall B

Time: Wednesday, February 20, 2019, 9:00 a.m. – 5:00 p.m. CT (poster displayed) and 6:45 p.m. – 7:45 p.m. CT (presentation)
Title: Ex Vivo Nicotinamide-Expanded (NAM-Expanded) Unrelated Cord Blood Transplantation (UCB) for Refractory Severe Aplastic Anemia Results in Rapid Engraftment and Expedites Immune Recovery
Poster Number: 295
Lead Author: Joseph Clara, M.D.,Hematology Branch, National Heart, Lung, and Blood Institute
Location: George R. Brown Convention Center, Level 3, Hall B

Time: Saturday, February 23, 2019, 4:45 p.m. – 5:00 p.m. CT (oral presentation)
Title: Rapid and Robust CD4+ and CD8+ T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation
Abstract Number: 69
Lead Author: Jaap-Jan Boelens, M.D., Ph.D., Chief, Pediatric Stem Cell Transplantation and Cellular Therapies Service, Memorial Sloan Kettering Cancer Center
Location: Hilton Americas Houston, Grand Ballroom G

Gamida Cell applied the capabilities of its NAM-based cell expansion technology to highly functional NK cells to develop NAM-NK, an innate immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies. NAM-NK addresses key limitations of NK cells by increasing the cytotoxicity and in vivo retention and proliferation in the bone marrow and lymphoid organs of NK cells expanded in culture. NAM-NK is in Phase 1 development through an investigator-sponsored study in patients with refractory non-Hodgkin lymphoma and multiple myeloma.

GMDA stock

GMDA stock shows a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. A pullback is taking place, which may present a nice opportunity for an entry. There is a resistance zone just above the current price starting at $14.11. Right above this resistance zone may be a good entry point. There is a support zone below the current price at $13.88, a stop order could be placed below this zone.

BCRX Stock

BCX7353 – ZENITH-1 for angioedema attacks in patients with hereditary angioedema (HAE). Phase 2 data to be presented February 23, 2019 at AAAAI meeting.

BioCryst will present an abstract including results from the ZENITH-1 study at the upcoming annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) February 22-25, 2019, in San Francisco.

Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial; Session 2209, Urticaria and Angioedema, Poster 110, Moscone Center South, Exhibition Level, Hall B, Saturday, February 23, 9:45 a.m. PT

BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including BCX7353, an oral treatment for hereditary angioedema, galidesivir, a potential treatment for Marburg virus disease and Yellow Fever, and a preclinical program to develop oral ALK-2 inhibitors for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union.

BCRX stock chart

BCRX stock looks like a decent setup. There is reduced volatility while prices have been consolidating in the most recent period. There is a support zone below the current price at $8.96, a stop order could be placed below this zone.

AIMT Stock

AR101 for Peanut Allergy. BLA filing announced December 21, 2018. Phase 3 data to be presented on February 24, 2019 at the AAAAI Annual Meeting.

Aimmune Therapeutics announced that it will present data on AR101, oral immunotherapy, and peanut allergy at the 2019 American Academy of Asthma, Allergy and Immunology (AAAAI) Annual Meeting, taking place February 22–25 in San Francisco. All abstracts for the 2019 AAAAI Annual Meeting, which focuses on “Food Allergy: Advances in Prevention and Treatment,” are available at https://www.jacionline.org/issue/S0091-6749(18)X0004-9.

“We are excited by the new data being presented at AAAAI, which deepen our understanding of AR101 and how it may benefit children, teens and families struggling with the uncertainty of life with peanut allergy,” said Daniel Adelman, M.D., Chief Medical Officer of Aimmune. “Our goal with AR101 oral immunotherapy is to train the immune system so that allergic reactions with accidental exposures are less frequent and severe. Taken together, the new data presented at AAAAI help to elucidate how AR101 delivers on our therapeutic thesis, providing continued immunomodulation throughout the course of the treatment period studied, as evidenced by greatly reduced adverse events due to accidental exposures to peanuts. These data provide further evidence of the effects demonstrated in the exit food challenge in PALISADE, with a 94% reduction of epinephrine use in the AR101-treated patients at the 600-mg exit food challenge dose. Also, we are seeing increases in efficacy over time, as nearly two thirds of the AR101 patients who tolerated less than the highest dose at the PALISADE exit were able to tolerate more peanut protein in the follow-on study challenge, and half the patients overall were able to tolerate 2,000 mg as the single highest tolerated dose.”

Presentation details are as follows:

AR101 Clinical Trial Data

#P468:Wang et al., Impact of Peanut Allergy on Quality of Life: Baseline Results from PALISADE, a Phase 3, Double-Blind, Placebo-Controlled Trial for AR101 Oral Immunotherapy
Sunday, February 24, 9:45 a.m. – 10:45 a.m. PST
Moscone Center South, Exhibition Level, Hall B

#P742:Goldsobel et al., Identification of Peanut-Allergic Participants for Oral Immunotherapy with AR101 Using Clinical Reaction History and Immunologic Markers Without Oral Food Challenge – A Comparison Between RAMSES and PALISADE Trials
Monday, February 25, 9:45 a.m. – 10:45 a.m. PST
Moscone Center South, Exhibition Level, Hall B

#P776:Carr et al., Longer-Term Safety and Efficacy Measures of AR101 Oral Immunotherapy for Peanut Allergy: Results from a Phase 3 Follow-On Study
Monday, February 25, 9:45 a.m. – 10:45 a.m. PST
Moscone Center South, Exhibition Level, Hall B

#P796:Carr et al., Estimating the Probability of Tolerating Each Challenge Dose of Peanut Protein at Exit Double-Blind, Placebo-Controlled Food Challenge: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE) of AR101
Monday, February 25, 9:45 a.m. – 10:45 a.m. PST
Moscone Center South, Exhibition Level, Hall B

#P804:Hourihane et al., Accidental Exposures to Peanut and Other Food Allergens: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)
Monday, February 25, 9:45 a.m. – 10:45 a.m. PST
Moscone Center South, Exhibition Level, Hall B

#P819:Johnston et al., Prevalence of Comorbidities with Peanut Allergy: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)
Monday, February 25, 9:45 a.m. – 10:45 a.m. PST
Moscone Center South, Exhibition Level, Hall B

Additional Peanut Allergy and OIT Data

#P163:DunnGalvin et al., APPEAL (Allergy to Peanuts ImPacting Emotions and Life): Pan-European Results on Peanut Allergy Impact on Allergic Individuals, Parents and Caregivers
Saturday, February 23, 9:45 a.m. – 10:45 a.m. PST
Moscone Center South, Exhibition Level, Hall B

#P478:Mahr et al., High Comorbidity Burden and Rates of Severe Reactions in Young Patients with Peanut Allergy
Sunday, February 24, 9:45 a.m. – 10:45 a.m. PST
Moscone Center South, Exhibition Level, Hall B

#P810:Ciaccio et al., Preferences in Terminology Used to Describe Oral Immunotherapy Varies Based on Physician Utilization
Monday, February 25, 9:45 a.m. – 10:45 a.m. PST
Moscone Center South, Exhibition Level, Hall B

In addition, Aimmune will host a Corporate Symposium, “The Future of Food Allergy: Demystifying OIT,” on Friday, February 22, from 6:30 – 8:30 p.m. PST at the Marriott Marquis, Yerba Buena Salon 9.

AR101 is a complex biologic drug under investigation for the treatment of children and adolescents with peanut allergy. The U.S. Food and Drug Administration (FDA) granted AR101 Fast Track Designation for peanut allergy in September 2014 and Breakthrough Therapy Designation for peanut allergy in ages 4–17 in June 2015.

Aimmune Therapeutics is a biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age. Aimmune’s regulatory filing for marketing approval of AR101 in the United States (submitted 4Q18) and Europe (anticipated in 1H19) are based on data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in 4–17-year-old subjects met its primary and key secondary endpoints, and additional ongoing and completed AR101 clinical trials. Aimmune has filed an IND application for its second product, AR201, for the treatment of egg allergy and intends to start a randomized Phase 2 clinical trial in the first half of 2019.

AIMT stock chart

AIMT stock presents a nice setup opportunity. We see reduced volatility while prices have been consolidating in the most recent period. There is a very little resistance above the current price. There is a support zone below the current price at $23.58, a stop order could be placed below this zone.

Disclosure: I do not hold any position in any stock mentioned in this article.

Picture of SOFI artificial intelligence

SOFI AI For Premium Members